[New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed]

Lakartidningen. 2009;106(48):3254-6, 3258, 3260.
[Article in Swedish]
No abstract available

Publication types

  • Review

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Drug Approval
  • Drug Resistance, Viral / genetics
  • Drug Therapy, Combination
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Oligopeptides / therapeutic use
  • Proline / analogs & derivatives
  • Proline / therapeutic use
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*
  • Simeprevir
  • Sulfonamides / therapeutic use
  • Treatment Outcome
  • Viral Nonstructural Proteins / chemistry
  • Viral Nonstructural Proteins / genetics

Substances

  • Antiviral Agents
  • Heterocyclic Compounds, 3-Ring
  • Oligopeptides
  • Protease Inhibitors
  • Sulfonamides
  • Viral Nonstructural Proteins
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline
  • Simeprevir
  • NS-5 protein, hepatitis C virus